Industry news
Novartis completes sale of its influenza vaccines to CSL
Novartis has announced that it has completed effective July 31, 2015 the divestiture of its influenza vaccine unit to CSL Limited. This marks the end of a series of transactions previously announced and completed, that are focusing Novartis on its three leading businesses of global scale – pharmaceuticals, generics and eye care. The former Novartis influenza vaccines will be vested initially in a CSL subsidiary called bioCSL and then in October 2015 in a new subsidiary called Seqirus.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins